Gina Keller

I’m a PhD‑trained Medical Science Liaison and Medical Affairs leader with deep experience across rare diseases, oncology, immunology, and immune‑mediated disorders. My career has been built around one core mission: advancing innovative therapies for patients with high unmet need through scientific excellence, trusted relationships, and strategic field leadership.

Over the past decade, I’ve supported multiple product launches, partnered closely with clinical investigators, and built KOL networks from the ground up across academic centers, integrated health systems, and community practices. I thrive in fast‑moving biotech environments where scientific rigor, adaptability, and cross‑functional collaboration drive meaningful impact.

My background spans:

• Rare disease (PAH, ILD, neuroblastoma, uveal melanoma, scleroderma, immune‑mediated conditions)
• Oncology (uveal melanoma, cutaneous melanoma, lung, ovarian, endometrial, urothelial)
• Clinical development support for Phase 1–3 trials
• Evidence generation, insights reporting, and medical strategy alignment
• Medical education, advisory boards, and congress support
• Training, mentoring, and scientific leadership within Medical Affairs teams

I’m known for my ability to translate complex science into clear, actionable insights, build long‑term scientific partnerships, and support clinical programs with precision and integrity. Whether engaging KOLs, supporting investigators, or collaborating with internal teams, I bring curiosity, strategic thinking, and a genuine commitment to improving patient outcomes.

I’m currently exploring new opportunities across Medical Affairs and MSL roles—particularly in rare disease, immunology, and oncology—where I can contribute scientific expertise, field leadership, and a passion for advancing transformative therapies.

If you’re working in biotech, clinical development, or Medical Affairs, I’d love to connect.

I am a PhD‑trained Medical Science Liaison and Medical Affairs leader with more than a decade of experience advancing therapies in rare disease, oncology, immunology, and immune‑mediated disorders. My career spans both emerging biotechs and established pharmaceutical organizations, where I’ve built strong scientific partnerships, supported complex clinical programs, and delivered high‑value medical education across diverse healthcare settings.

I have extensive experience engaging Key Opinion Leaders, supporting Phase 1–3 clinical trials, and collaborating with investigators to improve recruitment, data quality, and protocol adherence. My background includes global MSL leadership, clinical scientist responsibilities, and hands‑on involvement in product launches, advisory boards, and scientific congresses.

Across every role, I’m known for translating complex science into clear, actionable insights, capturing meaningful field intelligence, and working cross‑functionally to shape medical strategy. I thrive in fast‑moving, mission‑driven environments and am passionate about bringing innovative therapies to patients with significant unmet needs.

• PhD, Molecular & Cellular Biology and Pathobiology – Medical University of South Carolina
• BS, Biology – Nebraska Wesleyan University